CD274 and neoplasm: Conversely, compared to its monovalent counterparts, the bispecific B10–B11 Nanofitin showed enhanced targeting on cells co-expressing both EGFR and PD-L1, enabling selective anti-tumor effects in vitro on MNNG-HOS tumor cells through PD-L1 neutralization, with the B10 Nanofitin having been shown to be unable to inhibit EGFR signaling [10].